YAP is often upregulated in drug‐resistant cancer cells, promoting cell survival, proliferation, and migration, which contributes to resistance against targeted therapies (e.g., trastuzumab, RAF/MEK inhibitors, temozolomide) and cytotoxic drugs [143, 144, 145, 146, 147, 148, 149, 150]. This evidence concerns the gene YAP1 and cancer.